Literature DB >> 18301292

The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype.

Jarosław Walkowiak1, Aleksandra Lisowska, Michal Blaszczyński.   

Abstract

(Table is included in full-text article.)Cystic fibrosis (CF) is the most frequent cause of exocrine pancreatic insufficiency in childhood. The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes CFTR protein that functions as cyclic AMP-dependent chloride channel allowing the passage of anions and secondarily water into the lumen of pancreatic ducts. Luminal chlorides are exchanged for bicarbonates. The lack of CFTR channel or its disrupted function (being the consequence of CFTR gene mutations) results in reduced volume of more acidic secretion. It has been suggested that such a situation leads to the precipitation of highly concentrated protein-containing secretion with obstruction and organ damage. The intensity of this process determines the progression of the disease. Steatorrhea is the significant symptom of classical form of CF. Residual pancreatic secretion in a subset of patients, however, allows for normal lipid digestion and absorption. Previous cross-sectional clinical studies estimated that about 85-90% of CF patients in preschool, school and older age are pancreatic insufficient. More frequent detection of mild and nonclassic forms of CF leads to higher frequency of pancreatic sufficiency (PS). The potential decline of exocrine pancreatic function, however, should be always considered. All PS patients with at least one severe or unknown CFTR mutation should be longitudinally assessed for the progression of pancreatic dysfunction. Recurrent acute and chronic pancreatitis is not a rare clinical condition in PS patients with PS: it might be the presenting symptom, even preceding CF diagnosis by several years. Potential appearance of this complication in individuals with pancreatic insufficiency demands elucidation.

Entities:  

Mesh:

Year:  2008        PMID: 18301292     DOI: 10.1097/MEG.0b013e3282f36d16

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  11 in total

Review 1.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

2.  Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets.

Authors:  Alicia K Olivier; Yaling Yi; Xingshen Sun; Hongshu Sui; Bo Liang; Shanming Hu; Weiliang Xie; John T Fisher; Nicholas W Keiser; Diana Lei; Weihong Zhou; Ziying Yan; Guiying Li; Turan I A Evans; David K Meyerholz; Kai Wang; Zoe A Stewart; Andrew W Norris; John F Engelhardt
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

3.  Atypical presentation of acute pancreatitis in a man with pancreatic insufficiency and cystic fibrosis: a case report.

Authors:  Malcolm Turner; Hugh Jackson; Robin Harle; Rob Bohmer; David W Reid
Journal:  J Med Case Rep       Date:  2010-08-18

Review 4.  The changing character of acute pancreatitis: epidemiology, etiology, and prognosis.

Authors:  Albert B Lowenfels; Patrick Maisonneuve; Thomas Sullivan
Journal:  Curr Gastroenterol Rep       Date:  2009-04

5.  Relationship Between Fat-Soluble Vitamin Supplementation and Blood Concentrations in Adolescent and Adult Patients With Cystic Fibrosis.

Authors:  Oranan Siwamogsatham; Wei Dong; Jose N Binongo; Ritam Chowdhury; Jessica A Alvarez; Shawna J Feinman; Jessica Enders; Vin Tangpricha
Journal:  Nutr Clin Pract       Date:  2014-04-17       Impact factor: 3.080

6.  Exogenous and endogenous determinants of vitamin K status in cystic fibrosis.

Authors:  Patrycja Krzyżanowska; Andrzej Pogorzelski; Wojciech Skorupa; Jerzy Moczko; Philip Grebowiec; Jarosław Walkowiak
Journal:  Sci Rep       Date:  2015-07-10       Impact factor: 4.379

7.  Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with Cystic Fibrosis.

Authors:  Valentina Maria Sofia; Cecilia Surace; Vito Terlizzi; Letizia Da Sacco; Federico Alghisi; Antonella Angiolillo; Cesare Braggion; Natalia Cirilli; Carla Colombo; Antonella Di Lullo; Rita Padoan; Serena Quattrucci; Valeria Raia; Giuseppe Tuccio; Federica Zarrilli; Anna Cristina Tomaiuolo; Antonio Novelli; Vincenzina Lucidi; Marco Lucarelli; Giuseppe Castaldo; Adriano Angioni
Journal:  Mol Med       Date:  2018-07-27       Impact factor: 6.354

8.  Leukocyte Telomere Length Is Not Reduced in Children and Adults with Cystic Fibrosis but Associates with Clinical Characteristics-A Cross-Sectional Study.

Authors:  Aleksandra Glapa-Nowak; Shivaprakash Jagalur Mutt; Aleksandra Lisowska; Ewa Sapiejka; Joanna Goździk-Spychalska; Mirosława Wieczorek-Filipiak; Sławomira Drzymała-Czyż; Jan Krzysztof Nowak; Olaf Thalmann; Karl-Heinz Herzig; Jarosław Walkowiak
Journal:  J Clin Med       Date:  2021-02-04       Impact factor: 4.241

9.  Green tea extract decreases starch digestion and absorption from a test meal in humans: a randomized, placebo-controlled crossover study.

Authors:  Klaudia Lochocka; Joanna Bajerska; Aleksandra Glapa; Ewa Fidler-Witon; Jan K Nowak; Tomasz Szczapa; Philip Grebowiec; Aleksandra Lisowska; Jaroslaw Walkowiak
Journal:  Sci Rep       Date:  2015-07-30       Impact factor: 4.379

10.  V232D mutation in patients with cystic fibrosis: Not so rare, not so mild.

Authors:  Ana E Fernández-Lorenzo; Ana Moreno-Álvarez; Cristóbal Colon-Mejeras; Francisco Barros-Angueira; Alfonso Solar-Boga; Josep Sirvent-Gómez; María L Couce; Rosaura Leis
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.